As part of the University at Buffalo, we are dedicated to high quality academic research, with a focus on translational use of quantitative neuroimaging metrics in neurological diseases and disorders like MS, Alzheimer’s, and stroke. We have published over 500 scholarly articles in peer-reviewed journals.
We provide cutting-edge quantitative outcome analytics for clinical and preclinical researchers and sponsors. We combine standards-based approaches with research expertise to deliver accurate, precise measures in compliance with regulatory oversight.
A key part of our mission at BNAC is to teach. We disseminate knowledge and train future neuroimagers, trained masters, and PhD students. We host fellowships for visiting doctors and research scholars. BNAC faculty have mentored and co-mentored hundreds of PhD students, MSc students, MD students, undergraduate students, neuroimaging fellows, and neurology residents.
Precise, advanced neuroimaging metrics to measure treatment effects while maximizing statistical power.
Full coordination with participating imaging centers from study initiation, individual site on-boarding, image acquisition, and analysis.
Strict adherence to the highest standards and regulatory requirements, including FDA/EMA, GCP, and ISO 9001:2015.
NeurologyLive®, a multimedia platform dedicated to providing health care professionals with direct access to expert-driven, practice-changing news and insights in neurology, welcomes Buffalo Neuroimaging Analysis Center to its Strategic Alliance Partnership (SAP) program.
Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR. Using the largest MRI-realworld multiple sclerosis dataset studied to date, the NeuroSTREAM-MSBase study, recently published in Neurogimage/Clinical, is the fruition of a collaboration between Sydney Neuroimaging Analysis Centre, Buffalo Neuroimaging Analysis Center (BNAC), MSBase and clinicians across the globe.
Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS.
-Wednesday, November 11, 2020
Thalamic Nuclei Volumes and Their Relationships to Neuroperformance in Multiple Sclerosis: A Cross-Sectional Structural MRI Study
-Monday, October 12, 2020
Subcutaneous anti-CD20 antibody treatment delays gray matter atrophy in human myelin oligodendrocyte glycoprotein-induced EAE mice
-Monday, September 28, 2020
Detection of Monocyte/Macrophage and Microglia Activation in the TMEV Model of Chronic Demyelination Using USPIO Enhanced Ultrahigh-Field Imaging
-Monday, August 31, 2020
Director of IT and Neuroinformatics Development
BNAC Director
Director of Sequence Development
